Institutions / Deerfield Management Company, L.P. / Activity
Activity — Deerfield Management Company, L.P.
10 moves.
| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| Q1 2026 as of | New | Veradermics, Inc Common stock | $315.8K | +5K | 5,000 <0.01% of portfolio | low |
| Q1 2026 as of | New | SGP SpyGlass Pharma, Inc. Common Stock | $14.25M | +550K | 550,000 0.21% of portfolio | medium |
| Q1 2026 as of | New | Bright Minds Biosciences Inc. Common stock | $20.65M | +283K | 283,000 0.31% of portfolio | medium |
| Q1 2026 as of | New | Tyra Biosciences, Inc. Common stock | $21.03M | +549K | 549,000 0.31% of portfolio | medium |
| Q1 2026 as of | New | BioMarin Pharmaceutical Inc Common stock | $48.10M | +852K | 851,556 0.72% of portfolio | medium |
| Q1 2026 as of | New | 372303206 Common stock | $66.06M | +2.5M | 2,462,000 0.98% of portfolio | high |
| Q1 2026 as of | New | Pfizer Inc Common stock | $85.36M | +3.0M | 3,040,000 1.27% of portfolio | high |
| Q1 2026 as of | New | Dianthus Therapeutics, Inc. Common stock | $85.58M | +1.0M | 1,019,813 1.28% of portfolio | high |
| Q1 2026 as of | New | Syndax Pharmaceuticals Inc Common stock | $88.30M | +3.8M | 3,779,900 1.32% of portfolio | high |
| Q1 2026 as of | New | Indivior Pharmaceuticals, Inc. Common stock | $94.42M | +3.1M | 3,097,790 1.41% of portfolio | high |